Contact Us
Do you have questions about our products or services? We’re here to help. Contact a Roche representative in your region.
Article
Cervical Cancer and HPV Screening: Why Complete HPV DNA Detection Matters
Key takeaways
- Learn about recent shifts in cervical cancer screening and how evolving guidelines from HRSA, ACOG, ASCCP, ACS and USPSTF are shaping clinical practice.
- Discuss the essential features of an ideal cervical cancer screening test — including DNA detection, internal human cellularity controls, and upfront 16/18 genotyping.
Why Complete DNA Detection Matters in HPV Screening (17:07)
Join Denise Heaney, Ph.D., VP of Medical and Scientific Affairs at Roche Diagnostics, for an evidence-based clinical briefing on the evolution of cervical cancer screening. As major U.S. healthcare organizations—including USPSTF, ASCCP, ACS, ACOG, and HRSA—shift toward 5-year primary hrHPV screening intervals, choosing a frontline assay with complete diagnostic sensitivity is essential for patient safety.
Related content
IVD
For in vitro diagnostic use.
cobas® HPV Test
The cobas® HPV tests are automated qualitative in vitro tests for the detection of human papillomavirus (HPV) DNA in patient specimens.
The cobas® HPV tests are automated qualitative in vitro tests for the detection of human papillomavirus (HPV) DNA in patient specimens.
Health Topic: Cervical Cancer and HPV Screening
Roche provides a holistic solution for screening, triage, diagnosis, and patient management to help prevent cervical cancer.
HPV Self-Collection: Expanding Access to Cervical Cancer Screening
HPV self-collection offers an alternative to women and people with a cervix when more traditional screening options don’t work for them.
...